Ocrelizumab for the treatment of multiple sclerosis

References

• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis. Neurology. 2014;83:278–286.
   PubMed Web of Science ®Google Scholar
• Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356:63–66.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Ho P-R, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17:405–415.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Salvetti M, Lolli F, et al. B cells and multiple sclerosis. Lancet Neurol. 2008;7:852–858.
   PubMed Web of Science ®Google Scholar
• Wekerle H. B cells in multiple sclerosis. Autoimmunity. 2017;50:57–60.
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545–558.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: mechanisms and Immunotherapy. Neuron. 2018;97:742–768.
   PubMed Web of Science ®Google Scholar
• Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366:2008–2016.
   PubMed Web of Science ®Google Scholar
• Colombo M, Dono M, Gazzola P, et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol Baltim Md 1950. 2000;164:2782–2789.
   Google Scholar
• Kabat EA, Moore DH, Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest. 1942;21:571–577.
   PubMedGoogle Scholar
• Kostulas VK, Link H, Lefvert AK. Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch Neurol. 1987;44:1041–1044.
   PubMedGoogle Scholar
• Tintore M, Rovira À, Río J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain J Neurol. 2015;138:1863–1874.
   Google Scholar
• Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–717.
   PubMed Web of Science ®Google Scholar
• Breij ECW, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol. 2008;63:16–25.
   PubMed Web of Science ®Google Scholar
• Barnett MH, Parratt JDE, Cho E-S, et al. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol. 2009;65:32–46.
   PubMed Web of Science ®Google Scholar
• Machado-Santos J, Saji E, Tröscher AR, et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain J Neurol. 2018;141:2066–2082.
   Google Scholar
• Harp CT, Ireland S, Davis LS, et al. Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol. 2010;40:2942–2956.
   PubMed Web of Science ®Google Scholar
• Ireland SJ, Guzman AA, Frohman EM, et al. B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses. J Neuroimmunol. 2016;291:46–53.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67:452–461.
   PubMed Web of Science ®Google Scholar
• Ireland SJ, Blazek M, Harp CT, et al. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity. 2012;45:400–414.
   PubMed Web of Science ®Google Scholar
• Bao Y, Cao X. The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review. J Autoimmun. 2014;55:10–23.
   PubMed Web of Science ®Google Scholar
• Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015;15:441–451.
   PubMed Web of Science ®Google Scholar
• Li R, Rezk A, Healy LM, et al. Cytokine-defined B cell responses as therapeutic targets in multiple sclerosis. Front Immunol. 2015;6:626.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell OW, Nicholas R, et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol. 2018;83:739–755.
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol Zurich Switz. 2004;14:164–174.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain J Neurol. 2007;130:1089–1104.
   Google Scholar
• Lucchinetti CF, Popescu BFG, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365:2188–2197.
   PubMed Web of Science ®Google Scholar
• Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain J Neurol. 2012;135:2925–2937.
   Google Scholar
• Touil H, Kobert A, Lebeurrier N, et al. Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis. J Neuroinflammation. 2018;15:114.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–688.
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460–471.
   PubMed Web of Science ®Google Scholar
• Drugs@FDA: FDA approved drug products [Internet]. [cited 2018 Jun 26]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=103705.
   Google Scholar
• European medicines agency - find medicine - MabThera [Internet]. [cited 2018 Jun 26]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000165/human_med_000897.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet Lond Engl. 2012;380:1819–1828.
   PubMed Web of Science ®Google Scholar
• Thompson SAJ, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30:99–105.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89:1107–1116.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up efficacy and safety findings. Neurology. 2017;89:1117–1126.
   PubMed Web of Science ®Google Scholar
• Kappos L, Hartung H-P, Freedman MS, et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014;13:353–363.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90:e1805–e1814.
   PubMed Web of Science ®Google Scholar
• Fox E, Lovett-Racke AE, Gormley M, et al. Final results of a placebo controlled, phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS). ECTRIMS, Berlin, Germany. Abstract; 2018. p. 10–11.
   Google Scholar
• Agius MA, Klodowska-Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2017. doi:10.1177/1352458517740641.
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Beyer J, Howell K, et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother Hagerstown Md 1997. 2005;28:212–219.
   Google Scholar
• Dörner T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol. 2008;20:263–268.
   PubMed Web of Science ®Google Scholar
• Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol. 2008;35:1245–1255.
   PubMed Web of Science ®Google Scholar
• Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol Baltim Md 1950. 2014;193:580–586.
   Google Scholar
• Agahozo MC, Peferoen L, Baker D, et al. CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells? Mult Scler Relat Disord. 2016;9:110–117.
   PubMed Web of Science ®Google Scholar
• Schuh E, Berer K, Mulazzani M, et al. Features of human CD3+CD20+ T cells. J Immunol Baltim Md 1950. 2016;197:1111–1117.
   Google Scholar
• von Buedingen H-C. Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. ECTRIMS, Paris, France. Poster; 2017.
   Google Scholar
• Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2010;21:1870–1876.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:2652–2661.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2016;376:221–234.
   Web of Science ®Google Scholar
• Hauser S, Li D, Calabresi P, et al. Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of Ocrelizumab in patients with relapsing–remitting multiple sclerosis (RRMS) (S31.004). Neurology. 2013;80:S31.004.
   Web of Science ®Google Scholar
• Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67:707–714.
   PubMed Web of Science ®Google Scholar
• Laurent S. Effect of ocrelizumab on B and T cell immune repertoires in patients with relapsing multiple sclerosis. ECTRIMS, Paris, France. Poster; 2017.
   Google Scholar
• Ocrevus (ocrelizumab) [product characteristics] European  Medicines Agency; 2018.
   Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet Lond Engl. 2011;378:1779–1787.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Brochet B, Montalban X, et al. Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. ECTRIMS, Berlin,Germany. Poster; 2018.
   Google Scholar
• Arnold DL, Kappos L, Hauser SL, et al. Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. ECTRIMS, Berlin, Germany. Poster; 2018.
   Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2016;376:209–220.
   Web of Science ®Google Scholar
• Filippini G. Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate. Evid Based Med. 2017;22:215–216.
   PubMedGoogle Scholar
• Ocrevus (ocrelizumab) [product information]. Roche; 2018.
   Google Scholar
• De Seze J. Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. ECTRIMS, London, UK. Poster; 2016
   Google Scholar
• Brown BA, Torabi M. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Saf. 2011;34:117–123.
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87:2074–2081.
   PubMed Web of Science ®Google Scholar
• Berger JR, Malik V, Lacey S, et al. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol. 2018;24:323–331.
   PubMed Web of Science ®Google Scholar
• PML reported in patient receiving Ocrelizumab [Internet]. Medscape. [cited 2018 May 24]. Available from: http://www.medscape.com/viewarticle/880654.
   Google Scholar
• Fine AJ, Sorbello A, Kortepeter C, et al. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol. 2014;75:108–115.
   PubMed Web of Science ®Google Scholar
• Wattjes MP, Killestein J. Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true? Ann Neurol. 2014;75:462.
   PubMed Web of Science ®Google Scholar
• Kadish R, Robertson D, Sweeney M. Fatal leukoencephalopathy in a patient with multiple sclerosis following treatment with ocrelizumab (P5.353). Neurology. 2018;90 (15 Suppl):P5.353.
   Google Scholar
• Wadström H, Frisell T, Askling J, et al. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med. 2017;177:1605–1612.
   PubMed Web of Science ®Google Scholar
• Hauser S, Kappos L, Montalban X, et al. Safety of Ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis (S36.001). ECTRIMS, Berlin, Germany. Poster; 2018.
   Google Scholar
• Stokmaier D, Winthrop K, Chognot C, et al. Effect of Ocrelizumab on vaccine responses in patients with multiple sclerosis (S36.002). Neurology [Internet]. 2018;90. Available from: http://n.neurology.org/content/90/15_Supplement/S36.002.abstract
   Google Scholar
• Commissioner O of the press announcements - FDA approves new drug to treat multiple sclerosis [Internet]. [cited 2018 May 24]. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm549325.htm.
   Google Scholar
• European medicines agency - news and events - new medicine for multiple sclerosis [Internet]. [cited 2018 May 24]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/11/news_detail_002847.jsp&mid=WC0b01ac058004d5c1.
   Google Scholar
• Ocrevus (ocrelizumab) [product characteristics] Health Canada; 2018.
   Google Scholar
• Ocrevus (ocrelizumab) [product characteristics] Food and Drug Administration; 2017.
   Google Scholar
• Haute Autorité de Santé - OCREVUS (SEP d’emblée progressive) [Internet].[cited 2018 Sep 10]. Available from: https://www.has-sante.fr/portail/jcms/c_2863557/fr/ocrevus-sep-d-emblee-progressive
   Google Scholar
• European medicines agency - find medicine - Ocrevus [Internet]. [cited 2018 Sep 10]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004043/human_med_002187.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–758.
   PubMed Web of Science ®Google Scholar
• Ciron J, Audoin B, Bourre B, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018;174:255–264.
   PubMed Web of Science ®Google Scholar
• Sormani MP, Bruzzi P. Can we measure long-term treatment effects in multiple sclerosis?. Nat Rev Neurol. 2015;11:176–182.
   PubMed Web of Science ®Google Scholar